Eli Lilly to acquire Merida Biosciences for up to $2.88 billion in autoimmune push

Eli Lilly announced plans to acquire privately held Merida Biosciences for up to $2.88 billion in cash. The deal is part of Lilly's strategy to expand its portfolio of treatments for autoimmune diseases. No timeline for completing the transaction was provided.